急性髓系白血病患者TP53突变的临床与预后价值
该回顾性研究分析了265例新诊断AML患者,TP53异常发生率为7.5%,以错义突变为主且多位于DNA结合结构域。TP53异常与高龄、复杂核型及更短总生存相关,地西他滨联合CAG方案诱导治疗可能改善生存。
要点
- TP53异常见于7.5%的AML患者,多位于DNA结合结构域外显子5-8。
- TP53异常与高龄、复杂核型及更短中位OS显著相关。
- 地西他滨联合CAG方案诱导治疗的中位OS优于3+7方案。
核心结论
- TP53异常AML患者错义突变常见,突变位点主要位于DNA结合结构域,与高龄、复杂核型及更短OS相关。
- 以地西他滨为基础的诱导化疗及异基因造血干细胞移植可能提高TP53异常AML患者生存率。
研究设计与样本
- 回顾性分析2010年1月至2019年1月上海长海医院血液科265例新诊断且有初发靶向NGS数据的AML患者。
- 采用包含210个血液肿瘤相关基因的靶向测序技术进行突变分析。
主要发现
- 20例(7.5%)伴TP53异常,其中错义突变17例(6.4%),移码缺失突变2例(0.7%),剪切位点突变1例(0.4%)。
- 共检测到23种TP53突变,16个(69.6%)位于DNA结合结构域外显子5-8,4个位于外显子3-4,2个位于外显子10,1个为剪切位点突变。
- TP53异常患者中位年龄52(26-72)岁,高于无异常者的45(14-75)岁(P=0.008)。
- TP53异常患者复杂核型比例45.0%(9/20),高于无异常者的6.1%(15/245)(P<0.001)。
- TP53异常患者中位OS为14.1(95%CI 6.78-21.42)个月,短于无异常者的31.4(95%CI 13.20-49.59)个月(P=0.029)。
关键数值与推荐
- 20例TP53异常患者中4例采用「地西他滨+CAG」方案诱导,15例采用「3+7」方案,中位生存时间分别为30.0个月和12.5个月(P=0.018)。
- 多因素分析显示TP53、DNMT3A、USH2A基因异常及初发WBC>12.45×10^9/L是影响OS的独立预后不良因素。
临床怎么用
- 对初诊AML患者进行包含TP53的NGS检测,有助于识别高危亚群。
- TP53异常且适合强化疗者,可考虑以地西他滨为基础的诱导方案。
- TP53异常患者应评估异基因造血干细胞移植的可行性。
局限性
- 单中心回顾性研究,样本量有限。
- 地西他滨联合CAG方案亚组病例数少,需更多病例或多中心随机研究进一步证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinical and prognostic values of TP53 gene mutation in patients with acute myeloid leukemia (AML) . Methods: A retrospective analysis of 265 newly diagnosed AML patients with next-generation sequencing (NGS) data in the Hematology Department of Changhai Hospital from January 2010 to January 2019 was performed. Mutation analysis was carried out by targeted sequencing technology including 200 hematological malignancy related genes. The association of TP53 mutation with clinical features was analyzed. Results: Alterations in TP53 were found in 20 (7.5%) patients, including 17 case (6.4%) of missense mutations, 2 cases (0.7%) of frame-shift deletion mutations and 1 case (0.4%) of splicing sites mutation. A total of 23 kinds of TP53 mutations were detected, most of them (16, 69.6%) were located in the DNA binding domain of exon 5-8, 4 in the DNA binding domain of exon 3-4, 2 in exon 10 and 1 in splice site, respectively. The median age of patients with TP53 alterations was higher than those without [52 (26-72) years old vs 45 (14-75) years old, P= 0.008]. The frequency of complex karyotypes was higher in patients with TP53 alterations than those without [45.0% (9/20) vs 6.1% (15/245) , P<0.001]. Median overall survival (OS) of patients with TP53 alterations was shorter than those without[14.1 (95%CI 6.78-21.42) months vs 31.4 (95%CI 13.20-49.59) months, P=0.029]. The OS of patients treated with "Decitabine + CAG" was superior than that of patients treated with "3 + 7" regimen [30.0 (95%CI 27.35-38.84) months vs 12.5 (95%CI 5.80-19.19) months, P=0.018]. Multivariate analysis indicated that TP53, DNMT3A and USH2A alterations, WBC ≥ 12.45×10(9)/L had negative impacts on OS. Conclusion: The frequency of TP53 mutation was 7.5% in our cohort. Most mutations were located in the DNA binding domain. TP53 alterations were strongly associated with older age, complex karyotype and shorter OS. Decitabine-based induction chemotherapy and hematopoietic stem cell transplantation may improve OS, more cases and/or multicenter randomized studies are needed for further confirmation. 目的: 探讨伴TP53基因异常急性髓系白血病(AML)患者的临床特征及预后。 方法: 回顾性分析2010年1月至2019年1月上海长海医院血液科新诊断的有初发靶向二代测序(NGS)数据的265例AML患者临床资料。采用包含210个血液肿瘤相关基因的靶向测序技术进行突变分析。分析TP53基因突变和(或)缺失与临床特征之间的关系及其对患者生存的影响。 结果: 20例(7.5%)患者伴TP53基因异常,其中错义突变17例(6.4%),移码(缺失)基因突变2例(0.7%),剪切位点突变1例(0.4%)。共检测到23种TP53基因突变,其中4个位于DNA结合结构域第3~4号外显子,16个位于DNA结合结构域第5~8号外显子,2个位于第10号外显子,1个为剪切子突变。伴TP53基因异常患者平均突变基因个数(6.2个)与无TP53基因异常组(6.4个)差异无统计学意义(P=0.770)。TP53基因异常患者的中位年龄为52(26~72)岁,高于无TP53基因异常患者的45(14~75)岁(P=0.008);复杂核型比例(45.0%,9/20)显著高于无TP53异常组(6.1%,15/245)(P<0.001);中位总生存(OS)时间[14.1(95%CI 6.78~21.42)个月]较无TP53异常组[31.4(95%CI 13.20~49.59)个月]显著缩短(P=0.029)。20例伴TP53基因异常患者中4例采用"地西他滨+CAG"方案诱导治疗,15例采用"3+7"方案治疗,中位生存时间分别为30.0个月和12.5个月(P=0.018)。多因素分析中,TP53、DNMT3A、USH2A基因异常及初发WBC>12.45×10(9)/L是影响OS的独立预后不良因素。 结论: 伴TP53基因异常AML患者中错义突变常见,突变位点主要分布于DNA结合结构域。TP53基因异常与高龄、复杂核型相关,且常与多个基因突变相伴出现。以地西他滨为基础的诱导化疗及异基因造血干细胞移植可能会提高患者生存率。.
引用
- Zhang Y, Hu XX, Gao L, et al. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856443. doi:10.3760/cma.j.issn.0253-2727.2019.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。